All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in FLT3-mutated acute myeloid leukemia (AML)?
How could new treatment options improve outcomes in FLT3-mutated AML?
Daver begins by outlining the nature of FLT3 mutations in patients with AML, including their association with a higher-risk prognosis, before discussing first- and second-generation FLT3 inhibitors and the studies that explored these. Daver goes on to outline a study on a venetoclax + gilteritinib combination in relapsed/refractory FLT3-mutated AML and its promising efficacy. Finally, Daver discusses studies aiming to improve outcomes for different patient groups, utilizing varying dosages and therapeutic combinations.
Can pre-transplant MRD testing predict patients who are more likely to relapse?
During ASCO we spoke with Christopher Hourigan, National Institutes of Health, Bethesda, US. We asked, Can pre-transplant minimal residual disease testing (MRD) testing...
Outcomes with venetoclax in treating AML in real-world settings
The findings demonstrated that the venetoclax-based combination approach was associated with encouraging response rates in first-line settings. Response rates were also found to be...
Subscribe to get the best content related to AML delivered to your inbox